Last update 12 Dec 2024

BMS-986458

Overview

Basic Info

Drug Type
Molecular glue
Synonyms
BCL6 LDD, BMS 986458
Target
BCL6
Mechanism
BCL6 inhibitors(B-cell lymphoma 6 protein inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
Non-Hodgkin's lymphoma refractory
Inactive Indication-
Originator Organization
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Active Organization
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with BMS-986458
CTIS2023-506654-20-00 / Recruiting
A Phase 1/2, multi-center, Open-label, Dose-finding Study to evaluate the safety, tolerability,pharmacokinetics, and pharmacodynamics of BMS-986458, alone and in combination with antilymphomaagents in Subjects with Relapsed/Refractory non-Hodgkin lymphomas (R/R NHL) - CA123-1000
NCT06090539 / RecruitingPhase 1/2
A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
100 Clinical Results associated with BMS-986458
Login to view more data
100 Translational Medicine associated with BMS-986458
Login to view more data
100 Patents (Medical) associated with BMS-986458
Login to view more data
100 Deals associated with BMS-986458
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Hodgkin's lymphoma refractoryPhase 2
US
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
29 Dec 2023
Non-Hodgkin's lymphoma refractoryPhase 2
FR
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
29 Dec 2023
Non-Hodgkin's lymphoma refractoryPhase 2
DE
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
29 Dec 2023
Non-Hodgkin's lymphoma refractoryPhase 2
NL
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
29 Dec 2023
Non-Hodgkin's lymphoma refractoryPhase 2
ES
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
29 Dec 2023
Non-Hodgkin's lymphoma refractoryPhase 2
CH
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
29 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free